vs

Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and 22nd Century Group, Inc. (XXII). Click either name above to swap in a different company.

Opus Genetics, Inc. is the larger business by last-quarter revenue ($3.9M vs $3.5M, roughly 1.1× 22nd Century Group, Inc.). On growth, Opus Genetics, Inc. posted the faster year-over-year revenue change (-10.2% vs -12.0%). Over the past eight quarters, Opus Genetics, Inc.'s revenue compounded faster (50.3% CAGR vs -26.1%).

Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.

22nd Century Media was an American media company based in the suburbs of Chicago. The company was founded in 2005 and at one time published 14 weekly community newspapers. The publications had roughly 160,000 subscribers.

IRD vs XXII — Head-to-Head

Bigger by revenue
IRD
IRD
1.1× larger
IRD
$3.9M
$3.5M
XXII
Growing faster (revenue YoY)
IRD
IRD
+1.9% gap
IRD
-10.2%
-12.0%
XXII
Faster 2-yr revenue CAGR
IRD
IRD
Annualised
IRD
50.3%
-26.1%
XXII

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IRD
IRD
XXII
XXII
Revenue
$3.9M
$3.5M
Net Profit
$-2.8M
Gross Margin
Operating Margin
-79.2%
Net Margin
-79.4%
Revenue YoY
-10.2%
-12.0%
Net Profit YoY
53.0%
38.4%
EPS (diluted)
$-36.48

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRD
IRD
XXII
XXII
Q4 25
$3.9M
$3.5M
Q3 25
$3.1M
$4.0M
Q2 25
$2.9M
$4.1M
Q1 25
$4.4M
$6.0M
Q4 24
$4.3M
$4.0M
Q3 24
$3.9M
$5.9M
Q2 24
$1.1M
$7.9M
Q1 24
$1.7M
$6.5M
Net Profit
IRD
IRD
XXII
XXII
Q4 25
$-2.8M
Q3 25
$-17.5M
$5.5M
Q2 25
$-7.4M
$-3.4M
Q1 25
$-8.2M
$-4.3M
Q4 24
$-4.6M
Q3 24
$-7.5M
$-3.8M
Q2 24
$-7.8M
$-1.1M
Q1 24
$-7.1M
$-5.7M
Gross Margin
IRD
IRD
XXII
XXII
Q4 25
Q3 25
36.3%
Q2 25
29.9%
Q1 25
Q4 24
Q3 24
47.8%
Q2 24
51.3%
Q1 24
Operating Margin
IRD
IRD
XXII
XXII
Q4 25
-79.2%
Q3 25
-269.9%
-80.1%
Q2 25
-309.0%
-73.0%
Q1 25
-227.2%
-43.1%
Q4 24
-101.8%
Q3 24
-207.1%
-56.8%
Q2 24
-748.9%
-25.8%
Q1 24
-450.5%
-68.5%
Net Margin
IRD
IRD
XXII
XXII
Q4 25
-79.4%
Q3 25
-566.9%
136.8%
Q2 25
-257.5%
-83.4%
Q1 25
-187.5%
-72.7%
Q4 24
-113.3%
Q3 24
-194.6%
-63.2%
Q2 24
-698.3%
-14.0%
Q1 24
-415.3%
-88.7%
EPS (diluted)
IRD
IRD
XXII
XXII
Q4 25
$-36.48
Q3 25
$-0.25
$-0.28
Q2 25
$-0.12
$-13.61
Q1 25
$-0.24
$-2.50
Q4 24
$-42962.00
Q3 24
$-0.29
$-1760.26
Q2 24
$-0.30
$-593.72
Q1 24
$-0.29
$-395.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRD
IRD
XXII
XXII
Cash + ST InvestmentsLiquidity on hand
$45.1M
$7.1M
Total DebtLower is stronger
$708.0K
Stockholders' EquityBook value
$15.3M
$15.8M
Total Assets
$50.2M
$27.0M
Debt / EquityLower = less leverage
0.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRD
IRD
XXII
XXII
Q4 25
$45.1M
$7.1M
Q3 25
$30.8M
$4.8M
Q2 25
$32.4M
$3.1M
Q1 25
$41.8M
$1.1M
Q4 24
$30.3M
$4.4M
Q3 24
$36.6M
$5.3M
Q2 24
$41.4M
$1.3M
Q1 24
$47.2M
$1.5M
Total Debt
IRD
IRD
XXII
XXII
Q4 25
$708.0K
Q3 25
Q2 25
$3.2M
Q1 25
$3.9M
Q4 24
$6.7M
Q3 24
$7.0M
Q2 24
$7.5M
Q1 24
$14.7M
Stockholders' Equity
IRD
IRD
XXII
XXII
Q4 25
$15.3M
$15.8M
Q3 25
$6.0M
$18.4M
Q2 25
$17.5M
$5.6M
Q1 25
$5.1M
$3.6M
Q4 24
$6.7M
$4.0M
Q3 24
$34.3M
$3.5M
Q2 24
$40.6M
$-955.0K
Q1 24
$46.1M
$-11.6M
Total Assets
IRD
IRD
XXII
XXII
Q4 25
$50.2M
$27.0M
Q3 25
$36.1M
$32.4M
Q2 25
$38.7M
$22.4M
Q1 25
$48.2M
$21.5M
Q4 24
$36.9M
$21.7M
Q3 24
$40.4M
$26.2M
Q2 24
$44.8M
$24.1M
Q1 24
$51.8M
$24.6M
Debt / Equity
IRD
IRD
XXII
XXII
Q4 25
0.04×
Q3 25
Q2 25
0.57×
Q1 25
1.08×
Q4 24
1.66×
Q3 24
2.02×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRD
IRD
XXII
XXII
Operating Cash FlowLast quarter
$-35.3M
$2.7M
Free Cash FlowOCF − Capex
$2.7M
FCF MarginFCF / Revenue
77.3%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-7.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRD
IRD
XXII
XXII
Q4 25
$-35.3M
$2.7M
Q3 25
$-6.2M
$-4.0M
Q2 25
$-10.3M
$-3.5M
Q1 25
$-9.0M
$-3.0M
Q4 24
$-25.6M
$-4.4M
Q3 24
$-5.1M
$-3.0M
Q2 24
$-7.3M
$-4.7M
Q1 24
$-5.7M
$-2.3M
Free Cash Flow
IRD
IRD
XXII
XXII
Q4 25
$2.7M
Q3 25
$-4.0M
Q2 25
$-3.5M
Q1 25
$-3.0M
Q4 24
Q3 24
$-3.0M
Q2 24
$-4.8M
Q1 24
$-2.3M
FCF Margin
IRD
IRD
XXII
XXII
Q4 25
77.3%
Q3 25
-100.3%
Q2 25
-85.9%
Q1 25
-50.1%
Q4 24
Q3 24
-51.2%
Q2 24
-60.1%
Q1 24
-35.0%
Capex Intensity
IRD
IRD
XXII
XXII
Q4 25
0.5%
Q3 25
0.1%
Q2 25
0.7%
Q1 25
0.2%
Q4 24
0.0%
Q3 24
1.2%
Q2 24
0.8%
Q1 24
0.1%
Cash Conversion
IRD
IRD
XXII
XXII
Q4 25
Q3 25
-0.73×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons